Agnes Reschke

Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset

W. Foulkes, A. Shlien, R. McWilliams, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of clinical pathways to improve multidisciplinary care of high-risk pediatric oncology patients

K. Davis, K. Sakamoto, C. Aftandilian, 2022, Frontiers in Oncology.

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

Mariella G. Filbin, Shawn M. Gillespie, K. Davis, 2022, Nature.

Life without mismatch repair

M. Stratton, P. Campbell, M. Gerstung, 2021, bioRxiv.

Abstract CT031: GD2 CAR T cells mediate clinical activity and manageable toxicity in children and young adults with DIPG and H3K27M-mutated diffuse midline gliomas

K. Davis, K. Yeom, M. Monje, 2021, Clinical Trials.

GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas

Mariella G. Filbin, Shawn M. Gillespie, K. Davis, 2022 .

A rapid ELISA platform with no sample preparation requirement

H. Soh, T. Cornell, C. Dory, 2023, bioRxiv.

Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study.

K. Cole, D. Gass, A. Shlien, 2024, The Lancet. Oncology.

Sequential intravenous and intracerebroventricular GD2-CAR T-cell therapy for H3K27M-mutated diffuse midline gliomas

Snehit Prabhu, B. Sahaf, S. Partap, 2024, medRxiv.